Global Blood Therapeutics
Data Breaches, Cyber Attacks and Security Report

https://gbt.com  ᛫  Biotech & Pharmaceuticals
Last updated October 19, 2019

About Global Blood Therapeutics

Company Overview

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Valuation

Employees

CEO

Ted W. Love, M.D.

Location

Data Breaches and Security News

Global Blood Therapeutics Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Global Blood Therapeutics is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Global Blood Therapeutics

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Global Blood Therapeutics's security performance with other companies